Aurelius Data – Julie Armstrong
Aurelius Data – Julie Armstrong
Dan Humiston: [00:00:00] Today's show is brought to you by a new podcast produced by MJ bulls media called Hemp Barons. It's a weekly show about the hemp company's products and entrepreneurs who are using this amazing plant to change the world. Listen to a new show every Tuesday on i Tunes Spotify and Stitcher and if you like the show please subscribe rate and review.
Julie Armstrong: [00:00:23] I just need your age your sex your medical condition and then every time you use a product for that condition or additional conditions you will enter and what you're using it for how often you're using it and whether or not you think it's working. We basically want your medical marijuana to be as reliable for you as taking Tylenol.
Dan Humiston: [00:00:48] From MJBulls media it's the raising cannabis capital Show.
Dan Humiston: [00:00:56] I'm Dan Humiston and on today's show how this company is using actual use data to provide cannabis results reliability to medical professionals and their patients.
Dan Humiston: [00:01:14] Today on raising cannabis capital we are joined by Julie Armstrong from a Aurelius Data. Julie welcome to the show.
Julie Armstrong: [00:01:22] Thank you. Thanks for having me.
Dan Humiston: [00:01:24] Well Julie you're pharmacies and you have experience in the pharmaceutical industry and background in medical science. You can maybe answer this question for me and get us started is why is it so hard for us to find the correct cannabis for everybody's condition. It just seems like that should be a no brainer.
Julie Armstrong: [00:01:44] Well most drugs take about 24 years to go from a concept to becoming over-the-counter. They go through concept doing the testing going through all the phases of FDA. They get a brand name drug. They eventually become deemed safe enough to go to over-the-counter and in all that time there is a lot of research consumer education scientific analysis data all those things. Cannabis has kind of made that leap in about four years going from a stigmatized illegal drug to an over-the-counter drug and we kind of skipped all those steps in between. So people remember what they used cannabis for before but there was never any sort of restaurants where people shared information. To say this helps me with nausea has helped my headache. It's helped me sleep and none of that data was ever quantified or put into any kind of restaurants or resource that people could continue to add two year after year. So we're kind of lacking a lot of the steps in between that makes sense.
Dan Humiston: [00:02:49] I mean 24 years I didn't realize it was that long of a process.
Julie Armstrong: [00:02:53] They're saying now that it takes two point seven billion dollars to bring a drug to market and the FDA now has their fast tracking. So they've kind of dropped that number from 24 years to 17.
Julie Armstrong: [00:03:06] Still a long time especially when it comes to cannabis every day you're hearing Oh this works for this or oh this works for this or try this for this. I think it kind of creates a condition that needs to be corrected and hopefully that's what we're going to do.
Julie Armstrong: [00:03:21] I used to joke around that I had a bottle Marinol that sat on my shelf in the pharmacy until it expired every single time and they would never get prescribed. Part of that was because once one patient took it and they did not get the intended effect and that word of mouth would get around within the cancer community doctors believe or not still felt that there was a stigma attached to it because it was synthetic THC and felt like there were more respectable drugs out there like so France for nausea. Part of the problem was the trials that were done for Marinol long ago for never really repeated. We didn't have a lot of patients taking at so it was never reinforced that it was effective and that manufacturer spend a lot of money on it to keep that research up but yet a tremendous amount of money was spent on drugs like surgery or Phenergan for nausea. And the research and education got out to consumers much more easily. What we're missing in medical marijuana is the research and education of patients in a standardised way. We are going to create the platform for that documentation by listening to patients documenting what they're using their medications for matching data with the user demographic the medical condition and a lot of the medical parameters that should be taken in a regular medical history. What that will get us is a very complete picture of matching a demographic to a condition to the compounds that are working. We want to get to the point where I can tell you a fifty nine year old postmenopausal woman with migraines is using this particular topical three times a day with this dosage and that she is getting a ninety five percent efficacy rate meaning that it's working for her. Ninety five percent of the time and we want patients to be able to share that information so they can replicate their results with that exact compound not necessarily the strain but the exact compounds that we know are working for that condition.
Dan Humiston: [00:05:25] Ok but how do you intend to collect all this data.
Julie Armstrong: [00:05:29] So through our survey tool aura which is going to be a mobile app that all patients can access they will be able to do Insurance survey telling us about them and about their medical conditions. Anonymous I just need your age your sex your medical condition and then every time you use a product for that condition or additional conditions you will enter and what you're using it for how often you're using it and whether or not you think it's working.
Julie Armstrong: [00:05:57] We basically want your medical marijuana to be as reliable for you as taking Tylenol.
Dan Humiston: [00:06:03] Just a quick reminder that you can view each of the company's confidential pitch decks including how much they're raising and the terms of their deals on the MJbulls web site. Go to MJbulls.com to find the cannabis investment opportunity that's right for you.
Dan Humiston: [00:06:20] I got to say it's very ambitious or a large project that you're embarking upon but based on your experience and your team's backgrounds it seems well within your scope. We don't normally have a lot of companies on our show that are at your stage. It's really early in your company's lifespan and most of the time companies at your stage aren't zeroed in on their core business yet you know they kind of leave in all their options open and that's why we normally pass on companies. But in your case you guys are laser focused on this project. You know exactly what you need to do how you need to do it from a startup standpoint. You're way more mature than most startups that you're staying. Thank you. Tell us a little bit about what's next for you what you need in order to get this thing going.
Julie Armstrong: [00:07:06] Well we're definitely not a bunch of kids. We're all at the top of our games in our respective fields. My CSO has just done a successful exit show a very well last year at this company for his lab. My CEO came out of tech and two of the companies that had the largest D rounds that I've ever been raised which got exceedingly good people and we sort those out first. So we knew that we could execute. At this moment we don't have to be plant touching. We have multiple labs in our portfolio that will do analysis for us and the type of analysis that we are doing on the back end to identify the compounds that we feel are attractive for the medical conditions will be identified to keep learning a machine learning they will find those patterns for us what we're doing now is the mobile app is almost completely built out back into platform as being built out and the chemical analysis 3D graphing database that matches up with that is being built out. So we're raising revenue for that.
Julie Armstrong: [00:08:07] We are raising three million in seed funds right now. And then we plan to raise another 7 probably in December of this year and that will be to launch this and get it out to as many patients a year end users as we can. We have very good partnerships with social aid organizations right now to immediately get the survey out to their users. And one of those is RSA. They're very excited about the research component of this and as being able to immediately provide value to their user base.
Dan Humiston: [00:08:39] Right now you're in the middle of your seed round and it's a three million dollar seed round. Correct. We'll have this information on the MJBulls web site.
Julie Armstrong: [00:08:46] I'm excited to talk to anyone about this. I know it seems like a really big problem but it's also probably the most important problem facing the industry right now. We feel like this is absolutely something we can tackle we're already tackling yet. We have a tremendous amount of interest and partners. I think that we have enough users that we can definitely benchmark significant pieces of data and datasets that will advance the industry.
Dan Humiston: [00:09:11] Like you said it's good for the industry but it's good for the population as a whole. I know a lot of people are rooting for you to get this thing figured out. They said earlier it's a big project but I think you have the chops to get it done.
Dan Humiston: [00:09:25] Thank you.
Julie Armstrong: [00:09:25] Thanks for your time today.
Dan Humiston: [00:09:27] Thank you. Good luck.
Dan Humiston: [00:09:33] Thanks for listening to raising cannabis capital to learn more about today's guests or to become a guest. Visit our website at MJBulls.com. Today's show is produced by MJBulls Media with original music produced by Jamie Humiston I'm Dan Humiston and you've been listening to the raising cannabis capital podcast.
THIS IS AN AUTOMATED TRANSCRIPT AND THERE MAY BE INACCURATE AND OR INCORRECT COMPUTER TRANSLATIONS. DO NOT RELY ON THIS OR ANY TRANSCRIPT ON THE MJBULLS MEDIA WEBSITE.